by Jeffrey Crawford, MD; Bruce E. Johnson, MD; and Gregory J. Riely, MD, PhD
Older patients with advanced non–small cell lung cancer (NSCLC) differ individually in their ability to tolerate combined chemotherapy and radiatio......READ MORE
Early phase studies suggest that dual targeted therapy might have a role in the treatment of advanced non–small cell lung cancer (NSCLC). Dual targ......READ MORE
Given the large number of targeted therapies that are now available for non–small cell lung cancer (NSCLC), it is essential for patients to receive......READ MORE
by Jeffrey Crawford, MD; Bruce E. Johnson, MD; and Gregory J. Riely, MD, PhD
Dramatic advances have occurred in recent years in the treatment of non–small cell lung cancer (NSCLC). However, continued work is needed to achiev......READ MORE
Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the treatment of late-stage non–small cell lung cancer (NSCLC). Emerging ......READ MORE
Although targeted therapy has revolutionized the treatment of non–small cell lung cancer (NSCLC) in those who have specific oncogenetic alterations......READ MORE
